Losartan - The first of a new class of antihypertensive drugs

P. Chan, B. Tomlinson, S. M. Shieh

Research output: Contribution to journalArticle

Abstract

During the past few years, angiotensin-converting enzyme (ACE) inhibitors have become increasingly popular in the treatment of hypertension and heart failure, but they have some limitations, in particular the side effect of a dry cough which develops in up to 50% of Oriental patients and is thought to be caused by the potentiation of bradykinin by kininase II inhibition. This annoying dry cough may result in discontinuation of ACE inhibitors in many patients with heart failure as well as hypertension, although definitive studies have shown that the mortality in heart failure can be reduced with ACE inhibitor treatment. Recently, a new class of antihypertensive drugs, namely angiotensin II type 1 (AT1) receptor antagonists, has been approved; the first available one is losartan. Unlike ACE inhibitors, the angiotensin II receptor antagonists act at the receptor level, specifically blocking the effects of angiotensin II, the main effector peptide of the renin-angiotensin system. Therefore, theoretically, angiotensin II antagonists may provide greater efficacy than ACE inhibitors. Additionally, angiotensin II receptor antagonists apparently do not potentiate bradykinin, thus avoiding the side effect of the dry cough characteristic of ACE inhibitors. Conversely, angiotensin II receptor antagonists may lack some of the possible beneficial effects of bradykinin potentiation. Preliminary studies all have shown beneficial effects using losartan in various conditions such as hypertension, heart failure, nephrotic syndrome with dyslipidemia and chronic renal failure. The question whether angiotensin II receptor antagonists represent an advance over ACE inhibitors has not been resolved, and the information provided here represents a review of the present clinical studies. ACE inhibitors have been used for many years and a number of large clinical trials have clearly demonstrated their value. Comparable studies are required for angiotensin II receptor antagonists before a definitive conclusion can be drawn.

Original languageEnglish
Pages (from-to)59-72
Number of pages14
JournalActa Cardiologica Sinica
Volume13
Issue number2
Publication statusPublished - 1997

Fingerprint

Losartan
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Angiotensin Receptor Antagonists
Heart Failure
Cough
Bradykinin
Hypertension
Angiotensin II
Angiotensin II Type 1 Receptor Blockers
Nephrotic Syndrome
Peptidyl-Dipeptidase A
Renin-Angiotensin System
Dyslipidemias
Treatment Failure
Chronic Kidney Failure
Clinical Trials
Peptides
Mortality

Keywords

  • ACE inhibitor
  • Angiotensin II antagonist
  • Losartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Losartan - The first of a new class of antihypertensive drugs. / Chan, P.; Tomlinson, B.; Shieh, S. M.

In: Acta Cardiologica Sinica, Vol. 13, No. 2, 1997, p. 59-72.

Research output: Contribution to journalArticle

Chan, P, Tomlinson, B & Shieh, SM 1997, 'Losartan - The first of a new class of antihypertensive drugs', Acta Cardiologica Sinica, vol. 13, no. 2, pp. 59-72.
Chan, P. ; Tomlinson, B. ; Shieh, S. M. / Losartan - The first of a new class of antihypertensive drugs. In: Acta Cardiologica Sinica. 1997 ; Vol. 13, No. 2. pp. 59-72.
@article{fdc137ef91b34379b97a222e8a98119d,
title = "Losartan - The first of a new class of antihypertensive drugs",
abstract = "During the past few years, angiotensin-converting enzyme (ACE) inhibitors have become increasingly popular in the treatment of hypertension and heart failure, but they have some limitations, in particular the side effect of a dry cough which develops in up to 50{\%} of Oriental patients and is thought to be caused by the potentiation of bradykinin by kininase II inhibition. This annoying dry cough may result in discontinuation of ACE inhibitors in many patients with heart failure as well as hypertension, although definitive studies have shown that the mortality in heart failure can be reduced with ACE inhibitor treatment. Recently, a new class of antihypertensive drugs, namely angiotensin II type 1 (AT1) receptor antagonists, has been approved; the first available one is losartan. Unlike ACE inhibitors, the angiotensin II receptor antagonists act at the receptor level, specifically blocking the effects of angiotensin II, the main effector peptide of the renin-angiotensin system. Therefore, theoretically, angiotensin II antagonists may provide greater efficacy than ACE inhibitors. Additionally, angiotensin II receptor antagonists apparently do not potentiate bradykinin, thus avoiding the side effect of the dry cough characteristic of ACE inhibitors. Conversely, angiotensin II receptor antagonists may lack some of the possible beneficial effects of bradykinin potentiation. Preliminary studies all have shown beneficial effects using losartan in various conditions such as hypertension, heart failure, nephrotic syndrome with dyslipidemia and chronic renal failure. The question whether angiotensin II receptor antagonists represent an advance over ACE inhibitors has not been resolved, and the information provided here represents a review of the present clinical studies. ACE inhibitors have been used for many years and a number of large clinical trials have clearly demonstrated their value. Comparable studies are required for angiotensin II receptor antagonists before a definitive conclusion can be drawn.",
keywords = "ACE inhibitor, Angiotensin II antagonist, Losartan",
author = "P. Chan and B. Tomlinson and Shieh, {S. M.}",
year = "1997",
language = "English",
volume = "13",
pages = "59--72",
journal = "Acta Cardiologica Sinica",
issn = "1011-6842",
publisher = "Republic of China Society of Cardiology",
number = "2",

}

TY - JOUR

T1 - Losartan - The first of a new class of antihypertensive drugs

AU - Chan, P.

AU - Tomlinson, B.

AU - Shieh, S. M.

PY - 1997

Y1 - 1997

N2 - During the past few years, angiotensin-converting enzyme (ACE) inhibitors have become increasingly popular in the treatment of hypertension and heart failure, but they have some limitations, in particular the side effect of a dry cough which develops in up to 50% of Oriental patients and is thought to be caused by the potentiation of bradykinin by kininase II inhibition. This annoying dry cough may result in discontinuation of ACE inhibitors in many patients with heart failure as well as hypertension, although definitive studies have shown that the mortality in heart failure can be reduced with ACE inhibitor treatment. Recently, a new class of antihypertensive drugs, namely angiotensin II type 1 (AT1) receptor antagonists, has been approved; the first available one is losartan. Unlike ACE inhibitors, the angiotensin II receptor antagonists act at the receptor level, specifically blocking the effects of angiotensin II, the main effector peptide of the renin-angiotensin system. Therefore, theoretically, angiotensin II antagonists may provide greater efficacy than ACE inhibitors. Additionally, angiotensin II receptor antagonists apparently do not potentiate bradykinin, thus avoiding the side effect of the dry cough characteristic of ACE inhibitors. Conversely, angiotensin II receptor antagonists may lack some of the possible beneficial effects of bradykinin potentiation. Preliminary studies all have shown beneficial effects using losartan in various conditions such as hypertension, heart failure, nephrotic syndrome with dyslipidemia and chronic renal failure. The question whether angiotensin II receptor antagonists represent an advance over ACE inhibitors has not been resolved, and the information provided here represents a review of the present clinical studies. ACE inhibitors have been used for many years and a number of large clinical trials have clearly demonstrated their value. Comparable studies are required for angiotensin II receptor antagonists before a definitive conclusion can be drawn.

AB - During the past few years, angiotensin-converting enzyme (ACE) inhibitors have become increasingly popular in the treatment of hypertension and heart failure, but they have some limitations, in particular the side effect of a dry cough which develops in up to 50% of Oriental patients and is thought to be caused by the potentiation of bradykinin by kininase II inhibition. This annoying dry cough may result in discontinuation of ACE inhibitors in many patients with heart failure as well as hypertension, although definitive studies have shown that the mortality in heart failure can be reduced with ACE inhibitor treatment. Recently, a new class of antihypertensive drugs, namely angiotensin II type 1 (AT1) receptor antagonists, has been approved; the first available one is losartan. Unlike ACE inhibitors, the angiotensin II receptor antagonists act at the receptor level, specifically blocking the effects of angiotensin II, the main effector peptide of the renin-angiotensin system. Therefore, theoretically, angiotensin II antagonists may provide greater efficacy than ACE inhibitors. Additionally, angiotensin II receptor antagonists apparently do not potentiate bradykinin, thus avoiding the side effect of the dry cough characteristic of ACE inhibitors. Conversely, angiotensin II receptor antagonists may lack some of the possible beneficial effects of bradykinin potentiation. Preliminary studies all have shown beneficial effects using losartan in various conditions such as hypertension, heart failure, nephrotic syndrome with dyslipidemia and chronic renal failure. The question whether angiotensin II receptor antagonists represent an advance over ACE inhibitors has not been resolved, and the information provided here represents a review of the present clinical studies. ACE inhibitors have been used for many years and a number of large clinical trials have clearly demonstrated their value. Comparable studies are required for angiotensin II receptor antagonists before a definitive conclusion can be drawn.

KW - ACE inhibitor

KW - Angiotensin II antagonist

KW - Losartan

UR - http://www.scopus.com/inward/record.url?scp=0030860351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030860351&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030860351

VL - 13

SP - 59

EP - 72

JO - Acta Cardiologica Sinica

JF - Acta Cardiologica Sinica

SN - 1011-6842

IS - 2

ER -